Phio Pharmaceuticals Corp. (PHIO) is a Biotechnology company in the Healthcare sector, currently trading at $1.29. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Valuation: PHIO trades at a trailing Price-to-Earnings (P/E) of -1.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.05.
Net income is $9M (loss), growing at +5.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $0 against $20M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 49.37 (strong liquidity). Debt-to-assets is 0%. Total assets: $21M.
Analyst outlook: 2 / 2 analysts rate PHIO as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 65/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).
